Adicet Bio Inc (ACET)
Drugs • Health Care
July 21, 2026 Adicet Bio Set to Showcase Innovations at Canaccord Genuity 46th Annual Growth Conference Adicet Bio will showcase its advancements in allogeneic gamma delta T cell therapies at the Canaccord Genuity 46th Annual Growth Conference. The event includes a fireside chat with CEO Chen Schor, highlighting the company's commitment to innovative cancer treatments.
March 12, 2026 Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Adicet Bio reports positive Q4 2025 results, highlighting clinical advancements in autoimmune research and solid tumor therapies. The company is set for pivotal trials in 2026, demonstrating strong operational momentum.
March 12, 2026 Adicet Bio Inc. Reports 2025 Annual Financial Results: A Year of Progress Amidst Challenges Adicet Bio's 2025 annual report reveals advancements in its product pipeline, particularly with prula-cel and ADI-212, while facing financial challenges with a net loss of $116.8 million. The company is focused on securing future funding to support ongoing clinical trials and aims to make a significant impact in immuno-oncology and autoimmune therapies.
January 30, 2026 Adicet Bio to Showcase Innovative Therapies at Guggenheim Biotech Summit 2026 Adicet Bio will present its innovative allogeneic gamma delta T cell therapies at the Guggenheim Biotech Summit 2026. The company aims to revolutionize treatment for autoimmune diseases and cancer with its cutting-edge research.
January 07, 2026 Adicet Bio Inc. Provides Corporate Update and Anticipated Milestones for 2026 Adicet Bio, Inc. has provided a corporate update highlighting its progress and key milestones for 2026. The company is advancing its pipeline in autoimmune diseases and solid tumor therapies, with promising developments in clinical trials and regulatory engagements.
December 26, 2025 Adicet Bio Inc. Announces One-for-16 Reverse Stock Split Adicet Bio, Inc. will execute a one-for-16 reverse stock split effective December 30, 2025, to comply with Nasdaq's minimum bid price rule. This move reduces outstanding shares and aims to bolster the company's market position, ensuring continued investor confidence.
November 05, 2025 Adicet Bio Reports Promising Q3 2025 Financial Results and Strategic Updates Adicet Bio, a clinical-stage biotech firm, reported encouraging Q3 2025 financial results, showcasing positive data from its ADI-001 trial for autoimmune diseases. With reduced R&D costs and a strong cash position, the company is poised for significant developments in 2026.
November 05, 2025 Adicet Bio Inc. Reports Promising Developments in Q3 2025 Financials and Clinical Trials Adicet Bio Inc. released its Q3 2025 financial results, showcasing advancements in its product pipeline and promising clinical trial outcomes for ADI-001. Despite facing financial challenges, the company is strategically positioned for future growth with significant capital raises and focused product development.
October 28, 2025 Adicet Bio to Showcase Innovations at Guggenheim Healthcare Conference Adicet Bio will participate in the Guggenheim Healthcare Innovation Conference, showcasing its advancements in gamma delta T cell therapies. CEO Chen Schor will discuss innovative treatments for autoimmune diseases and cancer during a fireside chat on November 11, 2025.
October 16, 2025 Adicet Bio Doses First Patient in Phase 1 Trial for Treatment-Refractory Rheumatoid Arthritis Adicet Bio has marked a milestone by dosing its first patient in a Phase 1 trial for ADI-001, aimed at treatment-refractory rheumatoid arthritis. This trial is part of a broader initiative to develop therapies for various autoimmune diseases, underscoring the company's commitment to innovative treatments.
October 07, 2025 Adicet Bio Inc. Announces $80 Million Registered Direct Offering Adicet Bio, Inc. has announced a strategic $80 million registered direct offering to fund its allogeneic gamma delta T cell therapies targeting autoimmune diseases and cancer. The offering includes over 70 million shares of common stock and pre-funded warrants, with a closing date set for October 8, 2025.
October 07, 2025 Adicet Bio Announces Promising Preliminary Results from ADI-001 Phase 1 Study in Autoimmune Diseases Adicet Bio reported positive preliminary results from the ADI-001 Phase 1 trial for autoimmune diseases, revealing complete renal responses in patients with Lupus Nephritis and significant improvements in disease activity scores. The treatment demonstrated a favorable safety profile, paving the way for further development and potential FDA engagement.
September 30, 2025 Adicet Bio Inc. Announces Inducement Grant Under Nasdaq Listing Rule Adicet Bio, Inc. has announced an inducement grant of stock options to a new employee, aligning with its strategy to attract talent in developing innovative therapies. The awarded options come with a structured vesting schedule and comply with Nasdaq regulations.
August 07, 2025 Adicet Bio Inc. Reports Q2 2025 Financial Results: Strategic Repositioning Amid Clinical Advancements Adicet Bio Inc. reported a net income loss of $31.21 million in Q2 2025, reflecting financial challenges while advancing its product pipeline. The company is strategically reducing its workforce by 30% and prioritizing candidates like ADI-001, which has received Fast Track Designation from the FDA.
May 06, 2025 Adicet Bio Inc. Q1 2025 Financial Report: Navigating Challenges and Opportunities Adicet Bio Inc. reported a net income loss of $28.21 million in Q1 2025, driven by high operational costs linked to clinical trials. Despite these challenges, the company is advancing its lead candidate ADI-001, which received Fast Track Designation, signifying potential growth. Stakeholders are closely monitoring the firm as it navigates compliance and cash flow management.
May 06, 2025 Adicet Bio Inc. Reports First Quarter 2025 Financial Results and Strategic Updates Adicet Bio, Inc. shares its Q1 2025 financial results, highlighting advancements in its pipeline for autoimmune diseases and cancer. With new leadership and promising data milestones expected in the coming months, the company aims to enhance its position in the biotech sector.
April 30, 2025 Adicet Bio Grants Inducement Awards to New Hires Under Nasdaq Listing Rule 5635(c)(4) Adicet Bio has granted inducement awards in the form of stock options to three new employees, emphasizing its commitment to attracting top talent in biotech. The awards comply with Nasdaq regulations and are structured to promote long-term employee commitment.
April 30, 2025 Adicet Bio Inc. Set to Engage Investors at Citizens JMP Life Sciences Conference Adicet Bio, Inc. will engage investors at the Citizens JMP Life Sciences Conference on May 7-8, 2025, showcasing its advancements in gamma delta T cell therapies. The fireside chat with CEO Chen Schor will reveal strategic insights into their innovative approaches to autoimmune diseases and cancer treatments.
April 28, 2025 Adicet Bio Inc. Announces Key Presentation at ASGCT 28th Annual Meeting Adicet Bio, Inc. will present its innovative ADI-270 therapy at the ASGCT 28th Annual Meeting, showcasing its powerful anti-tumor activity. This presentation could significantly impact the future of cancer treatment and highlights Adicet's commitment to advancing biotechnological solutions.
April 17, 2025 Adicet Bio Strengthens Leadership with New Board Appointment Adicet Bio has appointed Michael Grissinger to its Board of Directors, bringing over 40 years of pharmaceutical experience. His expertise is expected to bolster the company's growth in gamma delta T cell therapies targeting autoimmune diseases and cancer.
March 31, 2025 Adicet Bio to Showcase Innovations at Canaccord Genuity Horizons in Oncology Conference Adicet Bio will participate in the Canaccord Genuity Horizons in Oncology Virtual Conference, featuring CEO Chen Schor discussing innovative CAR T therapies. The company focuses on allogeneic gamma delta T cell therapies to enhance treatment options for cancer and autoimmune diseases.
March 31, 2025 Adicet Bio Inc. Announces Inducement Grants as Part of Strategic Hiring Initiative Adicet Bio, Inc. has announced inducement grants for new hires, including stock options totaling 38,600 shares. This strategic initiative aims to attract top talent as the company expands its gamma delta T cell therapy pipeline, ensuring compliance with Nasdaq regulations.
March 06, 2025 Adicet Bio Inc. Reports Promising Developments in 2024 Annual Report Adicet Bio Inc.'s 2024 annual report reveals substantial progress in its gamma delta T cell therapies for autoimmune diseases and cancer. The company reported a reduced net loss and increased assets, while outlining its strategic R&D initiatives and the need for further funding to support future growth.
March 06, 2025 Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress Adicet Bio, a clinical-stage biotech firm, announced its Q4 2024 financial results and outlined significant progress in gamma delta T cell therapies. The company is advancing key clinical trials for autoimmune diseases and cancer, with promising data expected in 2025.
March 03, 2025 Adicet Bio Inc. to Showcase Promising ADI-270 Data at SITC 2025 Spring Scientific Meeting Adicet Bio, Inc. will present significant findings on its investigational product, ADI-270, at the SITC 2025 Spring Scientific Meeting. The data highlights improved efficacy and safety in preclinical models and early clinical results from a Phase 1/2 study targeting relapsed or refractory clear cell renal cell carcinoma.
February 27, 2025 Adicet Bio Secures FDA Fast Track Designation for ADI-001 in Systemic Sclerosis Treatment Adicet Bio announced FDA Fast Track Designation for ADI-001, an innovative therapy targeting systemic sclerosis and other autoimmune conditions. The designation accelerates development and highlights the company's commitment to addressing unmet medical needs.
February 09, 2025 SWOT Analysis of Adicet Bio Inc (2025) This SWOT analysis examines Adicet Bio Inc., focusing on its strengths like a strong IP portfolio and innovative therapies, while addressing weaknesses, opportunities for growth, and competitive threats. The insights reveal the company's strategic position in the biotechnology sector as of 2025.
February 05, 2025 Adicet Bio Secures FDA Fast Track Designation for ADI-001: A Promising Step Towards Treating Refractory SLE Adicet Bio has received FDA Fast Track Designation for ADI-001, a CAR T cell therapy targeting refractory systemic lupus erythematosus. This designation accelerates its development and review process, promising new treatment options for patients. The company is also expanding patient enrollment across various autoimmune conditions.
November 06, 2024 Adicet Bio Inc. Reports Promising Developments in 2024 Q3 Financial Results Adicet Bio Inc. reports significant advancements in Q3 2024, with a reduced net income loss and strong cash reserves. The company is focusing on expanding its product pipeline and strategic initiatives, particularly in China, while maintaining a robust financial position for future growth.
August 13, 2024 Adicet Bio Inc. Reports Q2 2024 Results: Progress in Clinical Trials and Financial Highlights Adicet Bio Inc. reported its Q2 2024 results, showcasing progress in clinical trials and a commitment to innovation in autoimmune disease treatments. Despite a net loss of $29.9 million, the company is strategically expanding its research and maintaining strong liquidity for future operations.
May 14, 2024 Adicet Bio Inc. Reports Q1 2024 Financial Results: A Promising Future Amid Challenges Adicet Bio Inc. reported its Q1 2024 financial results, showing a slight improvement in losses and a strong cash position. The company continues to focus on its innovative therapies while navigating challenges in clinical trials and capital requirements.